Non Small Cell Lung Carcinoma research hub
5 indexed studies · 4 currently recruiting
- recruitingPHASE1, PHASE2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
This study looks at new drug combinations for advanced lung cancer. It combines telisotuzumab adizutecan with immune-boosting drugs like budigalimab or pembrolizumab. The goal is to find safe and effective doses to help people with non-small cell lung cancer who haven't had prior treatment for advanced disease.
United States · Belgium · China - recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
This study looks at how well a treatment combining chemotherapy and amivantamab works for advanced lung cancer with specific gene changes. It helps us understand real-life results and safety for people already receiving this treatment through early access programs.
France - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE1
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This study looks at a new combination treatment for advanced breast cancer or a type of lung cancer. It combines two drugs, Trastuzumab deruxtecan and Pembrolizumab, to see if they are safe and effective together.
United States · France · Spain - recruitingPHASE3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
This study compares a new medicine, PF-08046054, with a standard lung cancer treatment, Docetaxel. It's for adults with a certain type of lung cancer that has already been treated and has a specific marker called PD-L1.
United States · Argentina · Australia